The increase in minimum quantities for the treatment of breast and lung cancer will lead to a significant concentration of care at hospital sites with a lot of routine in the respective procedures in 2025, which according to studies also show better treatment outcomes. According to the minimum quantity transparency map published today by AOK, the number of hospital sites involved in lung cancer treatment will decrease from 169 nationwide this year to 144 next year (minus 15 percent). The number of clinics receiving permission to perform breast cancer surgery will be reduced from 425 to 393 (minus 8 percent). A strong concentration process is also evident for complex pancreatic surgeries. The minimum quantities for the treatment of breast cancer (50 cases per year) and lung cancer (40 cases per year) were only newly introduced this year. They will be increased to 100 cases next year according to the specifications of the Joint Federal Committee (G-BA)... 

Summary Background and Objectives The timely determination and evaluation of laboratory parameters in patients with acute life- or organ-threatening diseases and conditions in the emergency department or intensive care units can be essential for diagnosis, initiation of therapy, and outcome. The aim of the position paper is to define the temporal requirements for the provision of laboratory medicine results in emergency and intensive care medicine. Requirements for point-of-care testing (POCT) and (central) laboratory can be derived from the urgency. Methodology Expert groups from the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) and the German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI) developed a classification of the urgency of laboratory determinations and recommendations on the required framework conditions and quality assurance, using national and international guidelines, review articles, and original papers. Results 3 levels of urgency for the determination of the most common laboratory parameters are defined based on the turnaround time: Emergency 1,… 

The 2024 US presidential election ended with a historic victory for Donald Trump over Vice President Kamala Harris. A detailed analysis of the election results shows the decisive factors for his success. Economic Factors The economy proved to be the most important campaign issue. 52% of registered voters rated economic issues as "extremely important" for their voting decision – the highest value since… Historic Victory for Donald Trump

The effects of Donald Trump's election victory on the German biotech and pharmaceutical industry are already proving to be severe. Immediate export losses German pharmaceutical exports to the USA are expected to plummet by 35%[1]. This is particularly critical, as the USA is the most important sales market for German pharmaceutical companies – Bayer, for example, generates a quarter of its revenue there[7]. Financial dimension According to the Institute of the German Economy (IW), the total damage to the German economy will amount to up to 180 billion euros in the next four years[8]. The pharmaceutical industry is among the most heavily affected sectors. Indirect effects The effects go beyond direct export losses: Compensation options There are certain offsetting effects due to rising exports to other markets: Company reactions So far, only 4% of the affected companies are planning concrete adjustment measures such as relocating production to the USA or changing supply chains[9]. However, this could change once Trump announces his intended...